Related Experiment Video
Updated: Jun 7, 2026

Generation of Hypoparathyroid Rats via Carbon-Nanoparticle-Assisted Parathyroidectomy
Published on: July 14, 2023
Transient hyperphosphatasemia in children revisited
Neta Dori1, Lily Levi, Tamar Stam
1Department of Pediatrics Pediatric Surgery, Bnai Zion Medical Center, Maccabi Health Services, Haifa, Israel.
Insights
Transient hyperphosphatasemia (TH) in children often presents with elevated bone alkaline phosphatase (ALP) and is frequently diagnosed in the latter half of the year. The exact cause remains unclear, suggesting a complex mechanism involving various stimuli.
Area of Science:
- Pediatric Endocrinology
- Clinical Biochemistry
- Medical Diagnostics
Background:
- Transient hyperphosphatasemia (TH) is a recognized condition, yet its origins and underlying mechanisms are not fully understood.
- Existing knowledge on TH lacks detailed clinical characterization, particularly in pediatric populations.
Purpose of the Study:
- To investigate the clinical features of children diagnosed with TH.
- To compare current findings with previous studies to enhance understanding of TH.
- To identify potential subgroups of children at higher risk for developing TH.
Main Methods:
- Retrospective analysis of 60 children diagnosed with TH between 2003-2008.
- Inclusion of 122 age, gender, and symptom-matched controls.
- Categorization of patients into subgroups based on presenting symptoms (infectious disease, failure to thrive, diarrhea, other).
- Utilized Hydragel ISO-PAL kits for ALP isoenzyme analysis.
Main Results:
- Elevated alkaline phosphatase (ALP) levels (mean 2311 U/L) were observed in TH patients, with no significant differences across symptom subgroups.
- The average duration of TH was 12 weeks.
- Bone isoenzyme of ALP was elevated in most analyzed cases.
- A majority of diagnoses (71%) occurred in the second half of the calendar year.
Conclusions:
- No definitive etiological explanation for TH was established in this study.
- TH is presumed to result from a complex interplay of factors leading to enzyme upregulation.
- Further research is needed to elucidate the precise pathophysiology of TH.
Objective:
Although transient hyperphosphatasemia (TH) has been well known for decades, its etiology and pathophysiology remain unclear. We aimed to study the clinical characteristics of children diagnosed with TH compared to older studies in order to expand our knowledge and understanding of this condition and to try and find a subgroup of children who are more prone to develop TH.
Methods:
We retrospectively studied 60 children diagnosed at Maccabi Health Services and Bnai Zion Medical Center, Haifa, Israel with TH between the years 2003-08. One hundred and twenty-two children matched by age, gender and presenting symptoms served as the control group. The patients were divided into four subgroups by their presenting symptoms: infectious disease 33%, failure to thrive 28%, diarrhea 15% and other 23%. The Hydragel 7 ISO-PAL and Hydragel 15 ISO-PAL kits were used for the identification and quantification of ALP isoenzymes in human serum.
Results:
The ALP levels of the study group were 805-8619 U\L (mean 2311 U\L), without differences between the subgroups. The mean duration of TH was 12 weeks. ALP isoenzymes levels were measured in one-third of the patients, and showed that the bone isoenzyme was elevated in most. Forty-three (71%) subjects were diagnosed in the second half of the calendar year.
Conclusions:
We could not establish an etiological explanation for TH. We presume that it is a complex mechanism in which different stimuli led to upregulation of the enzyme.
Related Concept Videos
Pharmacokinetics in Pediatric Patients: Drug Metabolism
Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption
Pharmacokinetics in Pediatric Patients: Drug Excretion
Roles of Electrolytes: Calcium and Phosphate
The calcium concentration in blood plasma is primarily regulated...
Urinary Tract Calculi II: Pathophysiology and Clinical Manifestations
Pharmacokinetics in Pediatric Patients: Drug Distribution

